Investigational cancer drugs targeting cell metabolism in clinical development

Bibliography

• Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011;11(2):85-95
   PubMed Web of Science ®Google Scholar
• Warburg O. On the origin of cancer cells. Science 1956;123(3191):309-14
   PubMed Web of Science ®Google Scholar
• DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008;7(1):11-20
   PubMed Web of Science ®Google Scholar
• Jang M, Kim SS, Lee J. Cancer cell metabolism: implications for therapeutic targets. Exp Mol Med 2013;45(10):e45
   PubMedGoogle Scholar
• Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005;202(3):654-62
   PubMed Web of Science ®Google Scholar
• Dhanalakshmi S, Singh R. Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy. Oncogene 2005;24(7):1188-202
   PubMed Web of Science ®Google Scholar
• Flaig TW, Glode M, Gustafson D, et al. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate 2010;70(8):848-55
   PubMed Web of Science ®Google Scholar
• Siegel AB, Narayan R, Rodriguez R, et al. A Phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma. Integr Cancer Ther 2014;13(1):46-53
   PubMed Web of Science ®Google Scholar
• Kim JW, Gao P, Liu YC, et al. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol 2007;27(21):7381-93
   PubMed Web of Science ®Google Scholar
• Pelicano H, Martin D, Xu R, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006;25(34):4633-46
   PubMed Web of Science ®Google Scholar
• Fang J, Quinones QJ, Holman TL, et al. The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. Mol Pharmacol 2006;70(6):2108-15
   PubMed Web of Science ®Google Scholar
• Floridi A, Bruno T, Miccadei S, et al. Enhancement of doxorubicin content by the antitumor drug lonidamine in resistant Ehrlich ascites tumor cells through modulation of energy metabolism. Biochem Pharmacol 1998;56(7):841-9
   PubMed Web of Science ®Google Scholar
• De Lena M, Lorusso V, Latorre A, et al. Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study. Eur J Cancer 2001;37(3):364-8
   PubMed Web of Science ®Google Scholar
• Portalone L, Lombardi A, Antilli A, et al. Treatment of inoperable non-small cell lung carcinoma stage IIIb and IV with cisplatin, epidoxorubicin, vindesine and lonidamine: a phase II study. Tumori 1998;85(4):239-42
   Web of Science ®Google Scholar
• Berruti A, Bitossi R, Gorzegno G, et al. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. J Clin Oncol 2002;20(20):4150-9
   PubMed Web of Science ®Google Scholar
• Pacini P, Rinaldini M, Algeri R, et al. FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results. Eur J Cancer 2000;36(8):966-75
   PubMed Web of Science ®Google Scholar
• Dwarakanath B, Jain V. Targeting glucose metabolism with 2-deoxy-D-glucose for improving cancer therapy. Future Oncol 2009;5(5):581-5
   PubMed Web of Science ®Google Scholar
• Landau BR, Laszlo J, Stengle J, Burk D. Certain metabolic and pharmacologic effects in cancer patients given infusions of 2-deoxy-D-glucose. J Natl Cancer Inst 1958;21(3):485-94
   PubMed Web of Science ®Google Scholar
• Maher JC, Krishan A, Lampidis TJ. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother Pharmacol 2004;53(2):116-22
   PubMed Web of Science ®Google Scholar
• Dwarakanath BS, Singh D, Banerji AK, et al. Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: present status and future prospects. J Cancer Res Ther 2009;5(Suppl 1):S21-6
   PubMed Web of Science ®Google Scholar
• Singh D, Banerji AK, Dwarakanath BS, et al. Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol 2005;181(8):507-14
   PubMed Web of Science ®Google Scholar
• Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008;452(7184):230-3
   PubMed Web of Science ®Google Scholar
• Zhou W, Liotta LA, Petricoin EF. Cancer metabolism and mass spectrometry-based proteomics. Cancer Lett 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Wong N, De Melo J, Tang D. PKM2, a central point of regulation in cancer metabolism. Int J Cell Biol 2013;2013:242513
   PubMedGoogle Scholar
• Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G. Metabolic targets for cancer therapy. Nat Rev Drug Discov 2013;12(11):829-46
   PubMed Web of Science ®Google Scholar
• Fujiwara S, Kawano Y, Yuki H, et al. PDK1 inhibition is a novel therapeutic target in multiple myeloma. Br J Cancer 2013;108(1):170-8
   PubMed Web of Science ®Google Scholar
• Michelakis ED, Webster L, Mackey JR. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 2008;99(7):989-94
   PubMed Web of Science ®Google Scholar
• Whitehouse S, Cooper RH, Randle PJ. Mechanism of activation of pyruvate dehydrogenase by dichloroacetate and other halogenated carboxylic acids. Biochem J 1974;141(3):761-74
   PubMed Web of Science ®Google Scholar
• Dunbar E, Coats B, Shroads A, et al. Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors. Invest New Drugs 2014;32(3):452-64
   PubMed Web of Science ®Google Scholar
• Shroads AL, Langaee T, Coats BS, et al. Human polymorphisms in the glutathione transferase zeta 1/maleylacetoacetate isomerase gene influence the toxicokinetics of dichloroacetate. J Clin Pharmacol 2012;52(6):837-49
   PubMed Web of Science ®Google Scholar
• Garon EB, Christofk HR, Hosmer W, et al. Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer. J Cancer Res Clin Oncol 2014;140(3):443-52
   PubMed Web of Science ®Google Scholar
• Xuan Y, Hur H, Ham IH, et al. Dichloroacetate attenuates hypoxia-induced resistance to 5-fluorouracil in gastric cancer through the regulation of glucose metabolism. Exp Cell Res 2014;321(2):219-30
   PubMed Web of Science ®Google Scholar
• Stuart SD, Schauble A, Gupta S, et al. A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process. Cancer Metab 2014;2(1):4
   PubMedGoogle Scholar
• Zachar Z, Marecek J, Maturo C, et al. Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo. J Mol Med 2011;89(11):1137-48
   PubMed Web of Science ®Google Scholar
• Pardee T, Lee K, Luddy J, et al. A phase I study of the safety, efficacy and pharmacokinetics of the first in class pyruvate dehydrogenase complex inhibitor CPI-613 in patients with advanced hematologic malignancies. Blood 2013;122(21):A486
   PubMedGoogle Scholar
• Lee K, Khaira D, Rodriguez R, et al. Long-term stable disease of stage IV pancreatic neuroendocrine tumors and without significant adverse effect by CPI-613, an investigational novel anti-cancer agent. Case Stud Case Rep 2011;1:137-45
   Google Scholar
• Senzer N, Bedell C, Maturo C, et al. CPI-613, an investigational novel anti-cancer agent, provides long-term stable disease without significant adverse effects in a patient with stage IV relapsed hepatocellular carcinoma. Case Stud Case Rep 2012;2(2):38-45
   Google Scholar
• Dimmer KS, Friedrich B, Lang F, et al. The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem J 2000;350(Pt 1):219-27
   PubMedGoogle Scholar
• Kennedy KM, Dewhirst MW. Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol 2010;6(1):127-48
   PubMed Web of Science ®Google Scholar
• Egler RA, Fernandes E, Rothermund K, et al. Regulation of reactive oxygen species, DNA damage, and c-Myc function by peroxiredoxin 1. Oncogene 2005;24(54):8038-50
   PubMed Web of Science ®Google Scholar
• Sen CK, Packer L. Antioxidant and redox regulation of gene transcription. FASEB J 1996;10(7):709-20
   PubMed Web of Science ®Google Scholar
• Doroshow JH. Redox modulation of chemotherapy-induced tumor cell killing and normal tissue toxicity. J Natl Cancer Inst 2006;98(4):223-5
   PubMed Web of Science ®Google Scholar
• Kawecki A, Adkins D, Cunningham C, et al. A phase II study of ARQ 501 in patients with advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2007;25:16509
   Google Scholar
• Shapiro G, Supko J, Ryan D, et al. Phase I trial of ARQ 501, an activated checkpoint therapy (ACT) agent, in patients with advanced solid tumors. J Clin Oncol 2005;23:3042
   Google Scholar
• Khong H, Dreisbach L, Kindler H, et al. A phase 2 study of ARQ 501 in combination with gemcitabine in adult patients with treatment naive, unresectable pancreatic adenocarcinoma. J Clin Oncol 2007;25:15017
   Google Scholar
• Nagai M, Vo NH, Shin Ogawa L, et al. The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells. Free Radic Biol Med 2012;52(10):2142-50
   PubMed Web of Science ®Google Scholar
• O’Day S, Gonzalez R, Lawson D, et al. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J Clin Oncol 2009;27(32):5452-8
   PubMed Web of Science ®Google Scholar
• O’Day SJ, Eggermont AM, Chiarion-Sileni V, et al. Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. J Clin Oncol 2013;31(9):1211-18
   PubMed Web of Science ®Google Scholar
• Khan G, Merajver S. Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm. Expert Opin Investig Drugs 2009;18(4):541-8
   PubMed Web of Science ®Google Scholar
• Lowndes SA, Adams A, Timms A, et al. Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors. Clin Cancer Res 2008;14(22):7526-34
   PubMed Web of Science ®Google Scholar
• Redman BG, Esper P, Pan Q, et al. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 2003;2003:9(5):1666-72
   Google Scholar
• Henry NL, Dunn R, Merjaver S, et al. Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer. Oncology 2007;71(3-4):168-75
   Web of Science ®Google Scholar
• Lin J, Zahurak M, Beer TM, et al. A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naive prostate cancer. Urol Oncol 2013;31(5):581-8
   PubMed Web of Science ®Google Scholar
• Schneider BJ, Lee JS-J, Hayman JA, et al. Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer. Invest New Drugs 2013;31(2):435-42
   PubMed Web of Science ®Google Scholar
• Bruce JY, Eickhoff J, Pili R, et al. A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate. Invest New Drugs 2012;30(2):794-802
   PubMed Web of Science ®Google Scholar
• Kulke MH, Chan JA, Meyerhardt JA, et al. A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors. Cancer Chemother Pharmacol 2011;68(2):293-300
   PubMed Web of Science ®Google Scholar
• Zhou Q, Gustafson D, Nallapareddy S, et al. A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer. Invest New Drugs 2011;29(2):340-6
   PubMed Web of Science ®Google Scholar
• Mehta MP, Shapiro WR, Phan SC, et al. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int J Radiat Oncol Biol Phys 2009;73(4):1069-76
   PubMed Web of Science ®Google Scholar
• Meyers CA, Smith JA, Bezjak A, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 2004;22(1):157-65
   PubMed Web of Science ®Google Scholar
• Trachootham D, Zhou Y, Zhang H, et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 2006;10(3):241-52
   PubMed Web of Science ®Google Scholar
• Dragovich T, Gordon M, Mendelson D, et al. Phase I trial of imexon in patients with advanced malignancy. J Clin Oncol 2007;25(13):1779-84
   PubMed Web of Science ®Google Scholar
• Bailey HH, Ripple G, Tutsch KD, et al. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. J Natl Cancer Inst 1997;89(23):1789-96
   PubMed Web of Science ®Google Scholar
• Coriat R, Alexandre J, Nicco C, et al. Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir. J Clin Invest 2014;124(1):262-72
   PubMed Web of Science ®Google Scholar
• Karlsson JOG, Kurz T, Flechsig S, et al. Superior therapeutic index of calmangafodipir in comparison to mangafodipir as a chemotherapy adjunct. Transl Oncol 2012;5(6):492
   PubMed Web of Science ®Google Scholar
• Bach SJ, Swaine D. The effect of arginase on the retardation of tumour growth. Br J Cancer 1965;19:379-86
   PubMed Web of Science ®Google Scholar
• Kuo MT, Savaraj N, Feun LG. Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes. Oncotarget 2010;1(4):246-51
   PubMedGoogle Scholar
• Story MD, Voehringer DW, Stephens LC, Meyn RE. L-asparaginase kills lymphoma cells by apoptosis. Cancer Chemother Pharmacol 1993;32(2):129-33
   PubMed Web of Science ®Google Scholar
• Ettinger LJ, Kurtzberg J, Voute P, et al. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia. Cancer 1995;75:1176-6
   PubMed Web of Science ®Google Scholar
• Hays JL, Kim G, Walker A, et al. A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: early closure for safety. Mol Clin Oncol 2013;1(3):565-9
   Google Scholar
• Ott PA, Carvajal RD, Pandit-Taskar N, et al. Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Invest New Drugs 2013;31(2):425-34
   PubMed Web of Science ®Google Scholar
• Tomlinson BK, Bomalaski JS, Diaz M, et al. Phase I trial of ADI-peg 20 plus docetaxel (DOC) in patients (pts) with advanced solid tumors. J Clin Oncol 2013;31(Suppl):abstract 2569
   Google Scholar
• Yang T, Lu S, Chao Y, et al. A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. Br J Cancer 2010;103(7):954-60
   PubMed Web of Science ®Google Scholar
• Ookhtens M, Kannan R, Lyon I, Baker N. Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor. Am J Physiol 1984;247(1 Pt 2):R146-53
   PubMed Web of Science ®Google Scholar
• Flavin R, Peluso S, Nguyen PL, Loda M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol 2010;6(4):551-62
   PubMed Web of Science ®Google Scholar
• Liu H, Liu JY, Wu X, Zhang JT. Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker. Int J Biochem Mol Biol 2010;1(1):69-89
   PubMedGoogle Scholar
• Shanafelt TD, Call TG, Zent CS, et al. Phase 2 trial of daily, oral polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer 2013;119(2):363-70
   PubMed Web of Science ®Google Scholar
• Dang L, Jin S, Su SM. IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med 2010;16(9):387-97
   PubMed Web of Science ®Google Scholar
• Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321(5897):1807-12
   PubMed Web of Science ®Google Scholar
• Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360(8):765-73
   PubMed Web of Science ®Google Scholar
• Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462(7274):739-44
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010;18(6):553-67
   PubMed Web of Science ®Google Scholar
• Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012;483(7390):474-8
   PubMed Web of Science ®Google Scholar
• Chaturvedi A, Cruz MMA, Jyotsana N, et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 2013;122(16):2877-87
   PubMed Web of Science ®Google Scholar
• Stein E, Tallman M, Pollyea D, et al. Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014. p. 5-9
   Google Scholar
• Swietach P, Hulikova A, Vaughan-Jones RD, Harris AL. New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation. Oncogene 2010;29(50):6509-21
   PubMed Web of Science ®Google Scholar
• Siebels M, Rohrmann K, Oberneder R, et al. A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol 2011;29(1):121-6
   PubMed Web of Science ®Google Scholar
• Belldegrun A, Kloepfer P, Fall B, et al. ARISER: a randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with high-risk ccRCC – results and implications for adjuvant clinical trials. J Clin Oncol 2013;31(Suppl):abstract 4507
   Google Scholar
• Dittrich C, Zandvliet A, Gneist M, et al. A phase I and pharmacokinetic study of indisulam in combination with carboplatin. Br J Cancer 2007;96(4):559-66
   PubMed Web of Science ®Google Scholar
• Siegel-Lakhai W, Zandvliet A, Huitema A, et al. A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours. Br J Cancer 2008;98(8):1320-6
   PubMed Web of Science ®Google Scholar
• Raftopoulos H, Escudier B, Renshaw G, et al. A phase II multicenter study of the cyclin-dependent kinase inhibitor indisulam in patients with progressive inoperable and/or metastatic renal cell carcinoma (RCC). J Clin Oncol 2004;22:4629
   Google Scholar
• Talbot DC, von Pawel J, Cattell E, et al. A randomized phase ii pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non–small cell lung cancer. Clin Cancer Res 2007;13(6):1816-22
   PubMed Web of Science ®Google Scholar
• Zhong C, Fan L, Yao F, et al. HMGCR is necessary for the tumorigenecity of esophageal squamous cell carcinoma and is regulated by Myc. Tumor Biol 2014;35:4123-9
   PubMed Web of Science ®Google Scholar
• Han JY, Lim KY, Yu SY, et al. A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer. Cancer 2011;117(10):2178-85
   PubMed Web of Science ®Google Scholar
• Hong JY, Nam EM, Lee J, et al. Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients. Cancer Chemother Pharmacol 2014;73(1):125-30
   PubMed Web of Science ®Google Scholar
• Han J-Y, Lee S-H, Yoo NJ, et al. A randomized phase II. study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non–small cell lung cancer. Clin Cancer Res 2011;17(6):1553-60
   PubMed Web of Science ®Google Scholar
• Advani AS, McDonough S, Copelan E, et al. SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia. Br J Haematol 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Karnevi E, Said K, Andersson R, Rosendahl AH. Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells. BMC Cancer 2013;13:235
   PubMedGoogle Scholar
• Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Med Oncol 2012;29(2):1314-27
   PubMed Web of Science ®Google Scholar
• Bost F, Sahra IB, Le Marchand-Brustel Y, Tanti JF. Metformin and cancer therapy. Curr Opin Oncol 2012;24(1):103-8
   PubMed Web of Science ®Google Scholar
• Pernicova I, Korbonits M. Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 2014;10(3):143-56
   PubMed Web of Science ®Google Scholar
• Ko EM, Walter P, Jackson A, et al. Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol 2014;132(2):438-42
   PubMed Web of Science ®Google Scholar
• Thompson AM. Molecular pathways: preclinical models and clinical trials with metformin in breast cancer. Clin Cancer Res 2014;20(10):2508-15
   PubMed Web of Science ®Google Scholar
• Aragón F, Perdigón G, de LeBlanc A. Modification in the diet can induce beneficial effects against breast cancer. World J Clin Oncol 2014;5(3):455
   PubMedGoogle Scholar